Clinical trials: Severe Hypertriglyceridemia
Severe Hypertriglyceridemia During Pregnancy
Safety Study of Fenofibrate During Pregnancy
The purpose of this study is to evaluate the safety of fenofibrate in severe hypertriglyceridemia pregnant women.
- Trial name
- NCT05883865
- Testing
- Fenofibrate
- Where
- China
- Volunteers
- 250 people
- Sponsor
- First People's Hospital of Hangzhou
Severe Hypertriglyceridemia (sHTG)
Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis
The primary objective is to determine the change in Triglyceride (TG) levels following 12 weeks of repeated Intravenous (IV) doses of evinacumab.
- Trial name
- NCT03452228
- Testing
- evinacumab
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients with fasting high triglyceride levels ≥500 mg/dL and <2000 mg/dL and normal renal function.
- Trial name
- NCT03001817
- Testing
- K-877, Fenofibrate
- Where
- 220 sites in United States, Belarus and 7 more
- Volunteers
- 551 people
- Sponsor
- Kowa Research Institute, Inc.
Severe Hypertriglyceridemia
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment
The purpose of this study is to evaluate the efficacy and safety of K-877 in adult patients With Fasting High Triglyceride Levels ≥500 mg/dL and <2000 mg/dL and Mild or Moderate Renal Impairment.
- Trial name
- NCT03011450
- Testing
- K-877, Fenofibrate
- Where
- 241 sites in United States, Belarus and 7 more
- Volunteers
- 471 people
- Sponsor
- Kowa Research Institute, Inc.
Severe Hypertriglyceridemia
Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL
To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and < 2000 mg/dL.
- Trial name
- AMPLIFY (NCT04662528)
- Testing
- MAT9001 (omega-3 pentaenoic acid)
- Sponsor
- Matinas Biopharma, Inc
Severe Hypertriglyceridemia, Mixed Dyslipidaemia
A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia
A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects with Severe Hypertriglyceridemia (INDIGO-1)
- Trial name
- INDIGO-1 (NCT02944383)
- Testing
- Gemcabene
- Where
- 49 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Severe Hypertriglyceridemia
The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)
The purpose of this study is to investigate the effects of SC401B (ethyl esters of eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] 2 (~1260 mg EPA+DHA), 4 (~2520 mg EPA+DHA) or 6 (~3780 mg EPA+DHA) capsules per day in…
- Trial name
- NCT01997268
- Testing
- SC401B 2 capsules, SC401B 4 capsules, SC401B 6 capsules
- Sponsor
- Sancilio and Company, Inc.
Severe Hypertriglyceridemia
Epanova® for Lowering Very High Triglycerides
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
- Trial name
- EVOLVE (NCT01242527)
- Testing
- omefas
- Where
- 68 sites in United States, Denmark and 5 more
- Volunteers
- 399 people
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis
This is a randomized, open-label crossover study. The primary objective of this study is to compare the relative bioavailability of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), docosapentaenoic acid (DPA), and the…
- Trial name
- ECLIPSEIV (NCT02189252)
- Testing
- Epanova, Lovaza
- Where
- 4 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation
The objectives of this study are to compare the relative bioavailabilities of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in plasma from a single dose of Epanova or Lovaza during periods of high- and low -fat…
- Trial name
- ECLIPSE (NCT01208961)
- Testing
- Epanova (4 g) and Lovaza (4 g), Lovaza (4 g) and Epanova (4 g)
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Severe Hypertriglyceridemia
Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia
The primary objective is to determine the efficacy of AKR963 compared to placebo and active comparator in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 1500 mg/dL.
- Trial name
- NCT01229566
- Testing
- AKR-963
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Trygg Pharma, Inc.